Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)

NCT06958328 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.

NCT NCT06958328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06958328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)
Lead sponsor
NRG Oncology
Phase
Phase 3
Overall status
Recruiting
Start date
August 21, 2025
Completion date
October 21, 2030
Enrollment
356 (estimated)
Sites
333

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced unresectable pancreatic ductal adenocarcinoma, stage ii pancreatic cancer ajcc v8, stage iii pancreatic cancer ajcc v8, stage iv pancreatic cancer ajcc v8